NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease

• Joshua J. Field ,

  * E-mail: joshua.field@bcw.edu

  Affiliations Medical Sciences Institute, Blood Center of Wisconsin, Milwaukee, Wisconsin, United States of America, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America

  http://orcid.org/0000-0001-8148-055X

  ⨯
• Elaine Majerus,

  Affiliation Department of Medicine, Washington University in St. Louis, St. Louis, Missouri, United States of America

  ⨯
• Kenneth I. Ataga,

  Affiliation University of North Carolina, Chapel Hill, North Carolina, United States of America

  ⨯
• Elliot P. Vichinsky,

  Affiliation Oakland Children’s Hospital, Oakland, California, United States of America

  ⨯
• Robert Schaub,

  Affiliation NKT Therapeutics, Waltham, Massachusetts, United States of America

  ⨯
• Robert Mashal,

  Affiliation NKT Therapeutics, Waltham, Massachusetts, United States of America

  ⨯
• David G. Nathan

  Affiliations Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Boston Children’s Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯